Company News
- CTD Holdings Announces Expanded Access Protocol using Intravenous Trappsol® Cyclo™ for Alzheimer’s Disease
Aug 13, 2018, 8:00 AM EDT - CTD is working to establish a second clinical trial site at Morristown Medical Center, Atlantic Health System, Morristown, NJ
Aug 6, 2018, 8:00 AM EDT - CTD to Present at National Niemann-Pick Disease Foundation Annual Conference
Jun 27, 2018, 8:00 AM EDT - FDA Authorizes CTD to Proceed with Extension Protocol to US Phase I Trappsol(R) Cyclo(TM) Trial for Niemann-Pick Disease Type C
Apr 30, 2018, 8:00 AM EDT - CTD Holdings Closes $2.00 Million Private Placement
Apr 23, 2018, 8:00 AM EDT - CTD Holdings Finalizes Cooperative Agreement for Alzheimer's Disease Research Program
Apr 19, 2018, 8:00 AM EDT - CTD Holdings Conducts Initial Review of Safety Data for its Phase I and Phase I/II Trials of Trappsol(R) Cyclo(TM) to Treat Niemann-Pick Disease Type C
Mar 29, 2018, 1:45 PM EDT - Randall M. Toig, M.D. Joins CTD Holdings Board of Directors
Mar 20, 2018, 8:00 AM EDT - CTD Holdings Announces FDA Authorization to Proceed with Single Patient IND for Use of Trappsol(R) Cyclo(TM) to Treat Alzheimer's Disease
Mar 12, 2018, 9:04 AM EDT - CTD Holdings Initiates Research Program to Explore Cyclodextrin Therapy for Alzheimer's Disease
Jan 29, 2018, 8:00 AM EST